Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.

Stocks | Futures | Watchlist | More
or

Acasti Pharma (ACST)

Acasti Pharma (ACST)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 40,997
  • Shares Outstanding, K 44,288
  • Annual Sales, $ 200 K
  • Annual Income, $ -19,680 K
  • 60-Month Beta 1.79
  • Price/Sales 203.06
  • Price/Cash Flow N/A
  • Price/Book 0.38
Trade ACST with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.14
  • Most Recent Earnings -0.09 on 02/14/22
  • Next Earnings Date 06/28/22
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/22
See More
  • Average Estimate -0.13
  • Number of Estimates 1
  • High Estimate -0.13
  • Low Estimate -0.13
  • Prior Year -0.24
  • Growth Rate Est. (year over year) +45.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.8200 +12.89%
on 05/12/22
1.2100 -23.50%
on 04/21/22
-0.2643 (-22.21%)
since 04/20/22
3-Month
0.8200 +12.89%
on 05/12/22
1.3500 -31.43%
on 04/04/22
-0.2543 (-21.55%)
since 02/18/22
52-Week
0.8200 +12.89%
on 05/12/22
5.4400 -82.98%
on 06/23/21
-3.0743 (-76.86%)
since 05/20/21

Most Recent Stories

More News
Acasti Pharma Announces Positive Results for Pharmacokinetic Bridging Study, With Intravenous GTX-104 Meeting All Endpoints

Bioavailability of IV GTX-104 compared favorably with the oral formulation of nimodipine, and no serious adverse events observed for GTX-104 Phase 3...

ACST.VN : 1.210 (unch)
ACST : 0.9257 (-2.56%)
36 of the Best Ideas Companies to Present at the Spring into Action - Best Ideas Investor Conference on May 16th - 20th, 2022

RALEIGH, NC / ACCESSWIRE / May 16, 2022 / The Spring into Action- Best Ideas Virtual Investor Conference will take place on May 16th - 20th, 2022, where 36 SmallCap, MicroCap and NanoCap public companies...

ACST : 0.9257 (-2.56%)
LPTH : 1.6300 (-5.73%)
RCAT : 1.8400 (+3.95%)
IONM : 2.40 (+1.35%)
PYR : 2.06 (+8.99%)
OSS : 4.06 (-6.88%)
MODD : 4.63 (-2.73%)
STRN : 1.7700 (+2.91%)
AEYE : 3.23 (-5.28%)
SMFL : 0.5201 (-5.44%)
LFMD : 2.05 (-1.44%)
SURG : 4.43 (+11.03%)
Acasti Pharma CEO to Present at Microcap Rodeo's Spring into Action Best Ideas Virtual Conference on May 16th

LAVAL, QC / ACCESSWIRE / May 12, 2022 / Acasti Pharma Inc. ("Acasti" or the "Company") (NASDAQ:ACST)(TSXV:ACST), today announced that Jan D'Alvise, Chief Executive Officer, has been invited to present...

ACST : 0.9257 (-2.56%)
ACST.VN : 1.210 (unch)
Acasti Pharma to Present at the B. Riley Securities' 2022 Virtual Neuro & Ophthalmology Conference on April 28th

LAVAL, Québec, April 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced...

ACST : 0.9257 (-2.56%)
ACST.VN : 1.210 (unch)
Acasti Pharma Appoints Healthcare Industry Leader Michael L. Derby to its Board of Directors

LAVAL, Quebec, March 25, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST) today announces that it...

ACST : 0.9257 (-2.56%)
ACST.VN : 1.210 (unch)
Acasti Pharma Announces Patents for GTX-104 in Europe, GTX-102 in the U.S. and GTX-101 in Japan

LAVAL, Québec, March 22, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), announces the...

ACST : 0.9257 (-2.56%)
ACST.VN : 1.210 (unch)
Acasti Pharma CEO to Present at the 32nd Annual Oppenheimer Healthcare Conference on March 16th

LAVAL, Quebec, March 09, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST), today announced that Jan...

ACST : 0.9257 (-2.56%)
ACST.VN : 1.210 (unch)
Acasti Pharma Celebrates Rare Disease Day

CEO Jan D’Alvise participates in educational interviews regarding rare diseases, including subarachnoid hemorrhage, ataxia-telangiectasia and postherpetic...

ACST : 0.9257 (-2.56%)
ACST.VN : 1.210 (unch)
New Strong Sell Stocks for February 23rd

ARR, ACST, and ATUS have been added to the Zacks Rank #5 (Strong Sell) List on February 23, 2022

ARR : 7.33 (+0.14%)
ACST : 0.9257 (-2.56%)
ATUS : 10.79 (+0.56%)
Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2022

Provides updates on key milestones: GTX-104 PK study remains on track for results to be reported in the first half of calendar 2022; GTX-102 and GTX-101...

ACST.VN : 1.210 (unch)
ACST : 0.9257 (-2.56%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Acasti Pharma Inc. is a biopharmaceutical company. It is focused on research, development and commercialization of krill oil based forms of omega-3 phospholipid therapies. CaPre (R), Acasti's only prescription drug candidate, is being developed to help prevent and treat hypertriglyceridemia. ONEMIA (R)...

See More

Key Turning Points

3rd Resistance Point 1.0438
2nd Resistance Point 1.0019
1st Resistance Point 0.9638
Last Price 0.9257
1st Support Level 0.8838
2nd Support Level 0.8419
3rd Support Level 0.8038

See More

52-Week High 5.4400
Fibonacci 61.8% 3.6752
Fibonacci 50% 3.1300
Fibonacci 38.2% 2.5848
Last Price 0.9257
52-Week Low 0.8200

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar